Cytokinetics | CYTK - Current Liabilities

Stock Price
75.85
Daily Change
-2.79 -3.55%
Monthly
15.94%
Yearly
144.68%
Q2 Forecast
74.33

Cytokinetics reported $199.18M in Current Liabilities for its fiscal quarter ending in March of 2026.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Amgen USD 24.96B 534M Mar/2026
Arca Biopharma USD 16.63M 1.26M Mar/2026
Bayer EUR 33.46B 875M Mar/2026
Biogen USD 3B 350.5M Mar/2026
Brainstorm Cell Therapeutics USD 11.76M 757K Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Capricor Therapeutics USD 33.64M 2.2M Mar/2026
Cytokinetics USD 199.18M 3.27M Mar/2026
Eisai JPY 387.67B 9.42B Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Exelixis USD 370.98M 34.67M Mar/2026
Geron USD 73.57M 40.25M Mar/2026
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
Ligand Pharmaceuticals USD 40.67M 3.22M Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Regeneron Pharmaceuticals USD 5.11B 739.3M Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026